KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Interest & Investment Income: 2010-2025

Historic Interest & Investment Income for Nektar Therapeutics (NKTR) over the last 8 years, with Sep 2025 value amounting to $2.8 million.

  • Nektar Therapeutics' Interest & Investment Income fell 17.98% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year decrease of 34.44%. This contributed to the annual value of $14.5 million for FY2024, which is 23.72% down from last year.
  • Nektar Therapeutics' Interest & Investment Income amounted to $2.8 million in Q3 2025, which was up 43.17% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' Interest & Investment Income peaked at $5.2 million during Q3 2023, and registered a low of $2.0 million during Q2 2025.
  • Moreover, its 3-year median value for Interest & Investment Income was $3.9 million (2024), whereas its average is $3.7 million.
  • Data for Nektar Therapeutics' Interest & Investment Income shows a maximum YoY slumped of 49.53% (in 2025) over the last 5 years.
  • Nektar Therapeutics' Interest & Investment Income (Quarterly) stood at $4.6 million in 2023, then plummeted by 36.28% to $2.9 million in 2024, then dropped by 17.98% to $2.8 million in 2025.
  • Its Interest & Investment Income was $2.8 million in Q3 2025, compared to $2.0 million in Q2 2025 and $2.9 million in Q1 2025.